A Biomimetic Collagen Derived Peptide Exhibits Anti-angiogenic Activity in Triple Negative Breast Cancer

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2014 Nov 11

PMID 25384034

Citations 9

Authors

Elena V Rosca

Marie-France Penet

Noriko Mori

Jacob E Koskimaki

Esak Lee

Niranjan B Pandey

Zaver M Bhujwalla

Aleksander S Popel

Affiliations

Soon will be listed here.

Abstract

We investigated the application of a mimetic 20 amino acid peptide derived from type IV collagen for treatment of breast cancer. We showed that the peptide induced a decrease of proliferation, adhesion, and migration of endothelial and tumor cells in vitro. We also observed an inhibition of triple negative MDA-MB-231 xenograft growth by 75% relative to control when administered intraperitoneally for 27 days at 10 mg/kg. We monitored in vivo the changes in vascular properties throughout the treatment using MRI and found that the vascular volume and permeability surface area product decreased significantly. The treatment also resulted in an increase of caspase-3 activity and in a reduction of microvascular density. The multiple mode of action of this peptide, i.e., anti-angiogenic, and anti-tumorigenic, makes it a viable candidate as a therapeutic agent as a monotherapy or in combination with other compounds.

Citing Articles

Antitumor Properties of Matrikines of Different Origins: Prospects and Problems of Their Application.

Popov A, Kozlovskaya E, Rutckova T, Styshova O, Vakhrushev A, Kupera E Int J Mol Sci. 2023; 24(11).

PMID: 37298452 PMC: 10253668. DOI: 10.3390/ijms24119502.

Anti-angiogenic collagen IV-derived peptide target engagement with αβ and αβ in ocular neovascularization models.

Lima E Silva R, Mirando A, Tzeng S, Green J, Popel A, Pandey N iScience. 2023; 26(2):106078.

PMID: 36844452 PMC: 9947312. DOI: 10.1016/j.isci.2023.106078.

Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide.

Mirando A, Patil A, Rafie C, Christmas B, Pandey N, Stearns V Oncoimmunology. 2020; 9(1):1760685.

PMID: 32923118 PMC: 7458646. DOI: 10.1080/2162402X.2020.1760685.

Computational modeling of synergistic interaction between αVβ3 integrin and VEGFR2 in endothelial cells: Implications for the mechanism of action of angiogenesis-modulating integrin-binding peptides.

Bazzazi H, Zhang Y, Jafarnejad M, Popel A J Theor Biol. 2018; 455:212-221.

PMID: 30036530 PMC: 6156791. DOI: 10.1016/j.jtbi.2018.06.029.

Biomimetic peptide display from a polymeric nanoparticle surface for targeting and antitumor activity to human triple-negative breast cancer cells.

Bressler E, Kim J, Shmueli R, Mirando A, Bazzazi H, Lee E J Biomed Mater Res A. 2018; 106(6):1753-1764.

PMID: 29424479 PMC: 6035748. DOI: 10.1002/jbm.a.36360.

References

Imoukhuede P, Popel A . Quantitative fluorescent profiling of VEGFRs reveals tumor cell and endothelial cell heterogeneity in breast cancer xenografts. Cancer Med. 2014; 3(2):225-44. PMC: 3987073. DOI: 10.1002/cam4.188. View

Bhujwalla Z, Artemov D, Natarajan K, Solaiyappan M, Kollars P, Kristjansen P . Reduction of vascular and permeable regions in solid tumors detected by macromolecular contrast magnetic resonance imaging after treatment with antiangiogenic agent TNP-470. Clin Cancer Res. 2003; 9(1):355-62. View

Carrato Mena A, Pulido E, Guillen-Ponce C . Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib. Anticancer Drugs. 2010; 21 Suppl 1:S3-11. DOI: 10.1097/01.cad.0000361534.44052.c5. View

Rose S . FDA pulls approval for avastin in breast cancer. Cancer Discov. 2012; 1(7):OF1-2. DOI: 10.1158/2159-8290.CD-ND112311OL-08. View

Rivera C, Rosca E, Pandey N, Koskimaki J, Bader J, Popel A . Novel peptide-specific quantitative structure-activity relationship (QSAR) analysis applied to collagen IV peptides with antiangiogenic activity. J Med Chem. 2011; 54(19):6492-500. PMC: 3195544. DOI: 10.1021/jm200114f. View

Backer M, Backer J . Imaging key biomarkers of tumor angiogenesis. Theranostics. 2012; 2(5):502-15. PMC: 3364556. DOI: 10.7150/thno.3623. View

Preusser M, Fulop G, Berghoff A, Heinzl H, Steger G, Greil R . Influence of the American ODAC statement on Austrian bevacizumab prescribing practice for metastatic breast cancer. Oncologist. 2012; 17(7):e13-7. PMC: 3399659. DOI: 10.1634/theoncologist.2012-0115. View

Raatschen H, Simon G, Fu Y, Sennino B, Shames D, Wendland M . Vascular permeability during antiangiogenesis treatment: MR imaging assay results as biomarker for subsequent tumor growth in rats. Radiology. 2008; 247(2):391-9. PMC: 4423757. DOI: 10.1148/radiol.2472070363. View

Lakshmikanthan S, Sobczak M, Chun C, Henschel A, Dargatz J, Ramchandran R . Rap1 promotes VEGFR2 activation and angiogenesis by a mechanism involving integrin αvβ₃. Blood. 2011; 118(7):2015-26. PMC: 3158727. DOI: 10.1182/blood-2011-04-349282. View

10.

Ivaska J, Heino J . Cooperation between integrins and growth factor receptors in signaling and endocytosis. Annu Rev Cell Dev Biol. 2011; 27:291-320. DOI: 10.1146/annurev-cellbio-092910-154017. View

11.

Gabor Miklos G . Bevacizumab in neoadjuvant treatment for breast cancer. N Engl J Med. 2012; 366(17):1638. DOI: 10.1056/NEJMc1202229. View

12.

Goel S, Fukumura D, Jain R . Normalization of the tumor vasculature through oncogenic inhibition: an emerging paradigm in tumor biology. Proc Natl Acad Sci U S A. 2012; 109(20):E1214. PMC: 3356659. DOI: 10.1073/pnas.1203794109. View

13.

Folkman J . Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285(21):1182-6. DOI: 10.1056/NEJM197111182852108. View

14.

West X, Meller N, Malinin N, Deshmukh L, Meller J, Mahabeleshwar G . Integrin β3 crosstalk with VEGFR accommodating tyrosine phosphorylation as a regulatory switch. PLoS One. 2012; 7(2):e31071. PMC: 3281915. DOI: 10.1371/journal.pone.0031071. View

15.

Karagiannis E, Popel A . Identification of novel short peptides derived from the alpha 4, alpha 5, and alpha 6 fibrils of type IV collagen with anti-angiogenic properties. Biochem Biophys Res Commun. 2007; 354(2):434-9. PMC: 1899480. DOI: 10.1016/j.bbrc.2006.12.231. View

16.

Karagiannis E, Popel A . A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells. Proc Natl Acad Sci U S A. 2008; 105(37):13775-80. PMC: 2544530. DOI: 10.1073/pnas.0803241105. View

17.

Ogan M, Schmiedl U, Moseley M, Grodd W, Paajanen H, Brasch R . Albumin labeled with Gd-DTPA. An intravascular contrast-enhancing agent for magnetic resonance blood pool imaging: preparation and characterization. Invest Radiol. 1987; 22(8):665-71. View

18.

Pathak A, Penet M, Bhujwalla Z . MR molecular imaging of tumor vasculature and vascular targets. Adv Genet. 2010; 69:1-30. PMC: 4921063. DOI: 10.1016/S0065-2660(10)69010-4. View

19.

Braghiroli M, Sabbaga J, Hoff P . Bevacizumab: overview of the literature. Expert Rev Anticancer Ther. 2012; 12(5):567-80. DOI: 10.1586/era.12.13. View

20.

Manegold C, Vansteenkiste J, Cardenal F, Schuette W, Woll P, Ulsperger E . Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer. Invest New Drugs. 2012; 31(1):175-82. PMC: 3553405. DOI: 10.1007/s10637-012-9842-6. View